ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Polycarbophil: Drug information

Polycarbophil: Drug information
(For additional information see "Polycarbophil: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Fiber Laxative [OTC];
  • Fiber-Lax [OTC];
  • FiberCon [OTC];
  • FT Fiber Laxative [OTC]
Pharmacologic Category
  • Antidiarrheal;
  • Fiber Supplement;
  • Laxative, Bulk-Producing
Dosing: Adult
Constipation

Constipation: General dosing guidelines (OTC labeling): Oral: 1.25 g calcium polycarbophil 1 to 4 times/day; maximum daily dose: 8 tablets (5 g)/24 hours.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric
Constipation or diarrhea

Constipation or diarrhea: General dosing guidelines (OTC labeling): Oral:

Children 6 to 12 years: 625 mg calcium polycarbophil 1 to 4 times/day.

Children ≥12 years: Refer to adult dosing.

Adverse Reactions

There are no adverse reactions listed in the manufacturer's labeling.

Warnings/Precautions

Other warnings/precautions:

• Administration: Taking products without adequate fluid may cause it to swell and block throat or esophagus; use with caution in patients who have difficulty swallowing.

• Self-medication (OTC labeling): When used for self-medication, do not take for >7 days. Contact health care provider if rectal bleeding occurs or for failure to have a bowel movement.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Fiber Laxative: 625 mg

Fiber Laxative: 625 mg [scored]

FiberCon: 625 mg

FiberCon: 625 mg [DSC] [scored]

FT Fiber Laxative: 625 mg

Generic: 625 mg

Tablet, Oral [preservative free]:

Fiber-Lax: 625 mg [scored; starch free]

Generic Equivalent Available: US

Yes

Pricing: US

Tablets (FiberCon Oral)

625 mg (per each): $0.12

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Oral: Administer with adequate fluids (8 oz of water or other fluids) with each dose. Administer ≥2 hours before or after other medications. Chew chewable tablets thoroughly before swallowing; do not swallow whole.

Administration: Pediatric

Oral: Administer with adequate fluids (≥8 oz of water or other fluids).

Use: Labeled Indications

Constipation: Relieves occasional constipation to help restore and maintain regularity.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha-Lipoic Acid: Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts. Management: Separate administration of alpha-lipoic acid from that of any calcium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral calcium-containing products at lunch or dinner. Risk D: Consider therapy modification

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Risk X: Avoid combination

Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a calcium salt is not recommended under fasting conditions. Risk D: Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Risk D: Consider therapy modification

Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir. Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir. Risk D: Consider therapy modification

Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. Risk X: Avoid combination

Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. Risk C: Monitor therapy

Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. Risk C: Monitor therapy

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Risk D: Consider therapy modification

DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. Risk C: Monitor therapy

Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food. Risk D: Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Risk D: Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Risk D: Consider therapy modification

Estramustine: Calcium Salts may decrease the absorption of Estramustine. Management: Administer estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. If coadministered with calcium salts, monitor for decreased estramustine therapeutic effects. Risk D: Consider therapy modification

Levonadifloxacin: Calcium Salts may decrease the serum concentration of Levonadifloxacin. Risk X: Avoid combination

Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride. Risk D: Consider therapy modification

Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts. Risk C: Monitor therapy

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Risk D: Consider therapy modification

Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction. Risk D: Consider therapy modification

Quinolones: Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents. Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration. Risk D: Consider therapy modification

Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Risk D: Consider therapy modification

Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat. Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products. Risk D: Consider therapy modification

Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate. Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction. Risk D: Consider therapy modification

Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May increase the serum concentration of Calcium Salts. Risk C: Monitor therapy

Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased. Risk D: Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation. Risk D: Consider therapy modification

Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products. Risk X: Avoid combination

Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. Risk C: Monitor therapy

Pregnancy Considerations

When administered with adequate fluids, use is considered acceptable for the treatment of occasional constipation during pregnancy (Wald 2003).

Dietary Considerations

Some products may contain calcium.

Mechanism of Action

Restoring a more normal moisture level and providing bulk in the patient's intestinal tract

Pharmacokinetics (Adult Data Unless Noted)

Onset: 12 to 72 hours.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Fibercon;
  • (BR) Brazil: Benestare | Muvinor;
  • (CN) China: Calcium polycarbophil;
  • (CO) Colombia: Fibercon | Fibrosyl;
  • (DE) Germany: Fibercon;
  • (DO) Dominican Republic: Konsyl fiber;
  • (EG) Egypt: Evaculax | Evak;
  • (IL) Israel: Fibercon;
  • (IN) India: Calibs | Carbocium | Fibotab | Normosys;
  • (IT) Italy: Modula 625;
  • (JO) Jordan: Fibercon;
  • (JP) Japan: Colonel | Polyful;
  • (KR) Korea, Republic of: Cabophil | Calyphil | Carbocon | Carbomil | Carcon | Carphil | Celcarcone | Ducon | Duomedi | Hilcon | Hylcon | Karpil | Newcon | Picon | Pilcon | Policron | Polycol | Polyvis | Pushcon | Recxil | Solcon | Sylcon | Tencon | Wellcon;
  • (KW) Kuwait: Fibercon;
  • (LB) Lebanon: Fibercon;
  • (PR) Puerto Rico: Calcium polycarbonate | Fiber | Fiber laxative | Fibercon | Polycarbophil;
  • (SA) Saudi Arabia: Fibercon;
  • (SE) Sweden: Fibercon;
  • (TW) Taiwan: Fiberphil | Mitrolan
  1. Equalactin (polycarbophil) [prescribing information]. Edison, NJ: Numark Brands Inc; December 2018.
  2. Fibercon (polycarbophil) [prescribing information]. Madison, NJ: Pfizer Inc; Received April 2021.
  3. Wald A. Constipation, diarrhea, and symptomatic hemorrhoids during pregnancy. Gastroenterol Clin North Am. 2003;32(1):309-322. [PubMed 12635420]
Topic 10065 Version 255.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟